BR112017006826A2 - novos monômeros e dímeros peptídicos a4ss7 antagonistas - Google Patents
novos monômeros e dímeros peptídicos a4ss7 antagonistasInfo
- Publication number
- BR112017006826A2 BR112017006826A2 BR112017006826A BR112017006826A BR112017006826A2 BR 112017006826 A2 BR112017006826 A2 BR 112017006826A2 BR 112017006826 A BR112017006826 A BR 112017006826A BR 112017006826 A BR112017006826 A BR 112017006826A BR 112017006826 A2 BR112017006826 A2 BR 112017006826A2
- Authority
- BR
- Brazil
- Prior art keywords
- dimers
- a4ss7
- peptide monomers
- binding
- peptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
resumo ?novos monômeros e dímeros peptídicos a4ß7 antagonistas? a invenção refere-se a compostos de dímeros peptídicos e compostos mo-nômeros peptídicos que inibem potentemente a ligação de a4ß7 à molécula de ade-são celular de endereçamento da mucosa (madcam) in vivo, com alta seletividade contra a ligação a4ß1 e têm elevada estabilidade em condições gastrointestinais.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462058510P | 2014-10-01 | 2014-10-01 | |
US201462058506P | 2014-10-01 | 2014-10-01 | |
US201562149257P | 2015-04-17 | 2015-04-17 | |
US201562192934P | 2015-07-15 | 2015-07-15 | |
PCT/US2015/053558 WO2016054411A1 (en) | 2014-10-01 | 2015-10-01 | NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017006826A2 true BR112017006826A2 (pt) | 2017-12-12 |
Family
ID=55631539
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017006826A BR112017006826A2 (pt) | 2014-10-01 | 2015-10-01 | novos monômeros e dímeros peptídicos a4ss7 antagonistas |
Country Status (13)
Country | Link |
---|---|
US (5) | US9809623B2 (pt) |
EP (1) | EP3200812B8 (pt) |
JP (1) | JP2017535527A (pt) |
KR (1) | KR20170108936A (pt) |
CN (1) | CN106999537B (pt) |
AU (1) | AU2015328002A1 (pt) |
BR (1) | BR112017006826A2 (pt) |
CA (1) | CA2962642A1 (pt) |
IL (1) | IL251260A0 (pt) |
MX (1) | MX2017004300A (pt) |
RU (1) | RU2017114414A (pt) |
SG (1) | SG11201702553RA (pt) |
WO (1) | WO2016054411A1 (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS62633B1 (sr) | 2013-03-15 | 2021-12-31 | Protagonist Therapeutics Inc | Analozi hepcidina i njihove primene |
JP6585162B2 (ja) | 2014-05-16 | 2019-10-02 | プロタゴニスト セラピューティクス, インコーポレイテッド | α4β7インテグリンチオエーテルペプチドアンタゴニスト |
RU2736637C9 (ru) | 2014-07-17 | 2021-02-08 | Протагонист Терепьютикс, Инк. | Пептидные ингибиторы рецептора интерлейкина-23 для перорального приема и их применение для лечения воспалительных заболеваний кишечника |
EP3201217A4 (en) | 2014-10-01 | 2018-07-18 | Protagonist Therapeutics Inc. | Novel cyclic monomer and dimer peptides having integrin antagonist activity |
BR112017006826A2 (pt) | 2014-10-01 | 2017-12-12 | Protagonist Therapeutics Inc | novos monômeros e dímeros peptídicos a4ss7 antagonistas |
US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
CN109071602B (zh) | 2015-11-11 | 2022-09-13 | 西兰制药公司 | 靶向α4β7整联蛋白的环肽 |
WO2017117411A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
US10407468B2 (en) | 2016-03-23 | 2019-09-10 | Protagonist Therapeutics, Inc. | Methods for synthesizing α4β7 peptide antagonists |
JP6656661B2 (ja) * | 2016-06-16 | 2020-03-04 | 国立大学法人 東京大学 | プレキシンの結合調節剤 |
US11111273B2 (en) | 2016-11-11 | 2021-09-07 | Zealand Pharma A/S | Cyclic peptides multimers targeting alpha-4-beta-7 integrin |
JP7274425B2 (ja) | 2017-05-10 | 2023-05-16 | ジーランド ファーマ アクティーゼルスカブ | α4β7インテグリンを標的とするホモデチック環状ペプチド |
EP3681900A4 (en) | 2017-09-11 | 2021-09-08 | Protagonist Therapeutics, Inc. | OPIOID AGONIST PEPTIDES AND THEIR USES |
WO2019147824A1 (en) | 2018-01-26 | 2019-08-01 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
CA3089868A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
EP3810085A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
AU2020311395A1 (en) | 2019-07-10 | 2022-02-03 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
CN115038457A (zh) * | 2020-01-10 | 2022-09-09 | 普罗塔格尼斯特治疗股份有限公司 | 用于使用α4β7整合素拮抗剂治疗炎性肠病的方法 |
JP7441955B2 (ja) | 2020-01-15 | 2024-03-01 | ヤンセン バイオテツク,インコーポレーテツド | インターロイキン23受容体のペプチド阻害剤および炎症性疾患を治療するためのその使用 |
US20230107927A1 (en) | 2020-02-28 | 2023-04-06 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
IL302996A (en) | 2020-11-20 | 2023-07-01 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of the interleukin-23 receptor |
Family Cites Families (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4684620A (en) | 1984-09-04 | 1987-08-04 | Gibson-Stephens Neuropharmaceuticals, Inc. | Cyclic polypeptides having mu-receptor specificity |
US4724229A (en) | 1986-09-30 | 1988-02-09 | Smithkline Beckman Corporation | Arg-arg-arg-vasopressin antagonists |
US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
DK0578728T3 (da) | 1991-04-05 | 1999-04-12 | Genentech Inc | Inhibitorer for aggregering af blodplader, hvilke inhibitorer har høj specificitet for GP IIbIIIa |
AU673731B2 (en) | 1993-06-03 | 1996-11-21 | Banyu Pharmaceutical Co., Ltd. | Novel endothelin antagonistic peptide |
US6037324A (en) | 1996-01-04 | 2000-03-14 | Leukosite, Inc. | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor |
US5990084A (en) | 1996-04-19 | 1999-11-23 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
GB9613112D0 (en) | 1996-06-21 | 1996-08-28 | Zeneca Ltd | Chemical compounds |
US7122623B2 (en) | 1996-07-12 | 2006-10-17 | Adherex Technologies, Inc. | Compounds and methods for modulating cell adhesion |
CA2264243C (en) | 1996-08-30 | 2004-10-05 | Novo Nordisk A/S | Glp-1 derivatives |
US5942492A (en) | 1996-11-12 | 1999-08-24 | Angstrom Pharmaceuticals, Inc. | Cyclic peptides that bind to urokinase-type plasminogen activator receptor |
AU8399998A (en) | 1997-07-11 | 1999-02-08 | Innerdyne, Inc. | Methods and systems for preparing and sealing radiation delivery structures |
US6818617B1 (en) | 1997-08-15 | 2004-11-16 | Temple University- Of The Commonwealth System Of Higher Education | EC-3, an inhibitor of α4β1 and α4β7 integrins |
WO1999026615A1 (en) | 1997-11-24 | 1999-06-03 | Merck & Co., Inc. | Cyclic amino acid derivatives as cell adhesion inhibitors |
EP1100473A2 (en) | 1998-07-28 | 2001-05-23 | InnerDyne, Inc. | Absorbable brachytherapy and chemotherapy delivery devices and methods |
CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
US6087334A (en) | 1998-08-21 | 2000-07-11 | Amylin Pharmaceuticals, Inc. | Anti-diabetic peptides |
AUPP616598A0 (en) | 1998-09-25 | 1998-10-15 | University Of Queensland, The | Auxiliary for amide bond formation |
AUPP616498A0 (en) | 1998-09-25 | 1998-10-15 | University Of Queensland, The | Synthesis of cyclic peptides |
AUPP660698A0 (en) | 1998-10-21 | 1998-11-12 | University Of Queensland, The | A method of protein engineering |
US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
DE60040333D1 (de) | 1999-03-17 | 2008-11-06 | Novo Nordisk As | Verfahren zur acylierung von peptiden und proteinen |
CN1350534A (zh) | 1999-04-12 | 2002-05-22 | 阿文蒂斯药物有限公司 | 作为整联蛋白拮抗剂的取代双环杂芳基化合物 |
WO2001068586A2 (en) | 2000-03-14 | 2001-09-20 | Novartis Ag | α4β1 AND α4β7 INTEGRIN INHIBITORS |
SK9072003A3 (en) | 2001-01-09 | 2003-11-04 | Merck Patent Gmbh | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
DE10107707A1 (de) | 2001-02-19 | 2002-08-29 | Wilex Biotechnology Gmbh | Antagonisten für alpha¶4¶beta¶7¶-Integrin |
AUPS039702A0 (en) | 2002-02-08 | 2002-03-07 | University Of Queensland, The | Common protein surface shapes and uses therefor |
US20030166138A1 (en) | 2002-02-21 | 2003-09-04 | Todd Kinsella | Cyclic peptides and analogs useful to treat allergies |
WO2004011650A2 (en) | 2002-07-24 | 2004-02-05 | Intercell Ag | Antigens encoded by alternative reading frame from pathogenic viruses |
US20040176293A1 (en) | 2002-12-18 | 2004-09-09 | Wyeth | Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof |
US20070032417A1 (en) | 2002-12-24 | 2007-02-08 | Walter And Eliza Hall Institute Of Medical Research | Peptides and therapeutic uses thereof |
EP1618131A2 (en) | 2003-04-15 | 2006-01-25 | Xenon Pharmaceuticals Inc. | Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof |
EP2332967B1 (en) | 2003-11-05 | 2016-04-20 | Dana-Farber Cancer Institute, Inc. | Stabilized alpha helical peptides and uses thereof |
EP1695255B1 (en) | 2003-12-19 | 2016-09-07 | Applied Biosystems, LLC | Methods and systems for protein and peptide evidence assembly |
AP2006003689A0 (en) | 2004-01-09 | 2006-08-31 | Pfizer | Antibodies to MAdCAM |
US8536140B2 (en) | 2004-03-12 | 2013-09-17 | Mti Meta Tech Inc. | Methods for treating inflammatory bowel disease |
NZ551934A (en) | 2004-06-24 | 2009-09-25 | Inst Medical W & E Hall | Conjugates comprising a targeting moiety and a peptide that mimics the apoptosis-inducing BH3-only proteins |
JP5154935B2 (ja) | 2004-09-23 | 2013-02-27 | ザ・ユニヴァーシティ・オブ・メルボーン | Porphyromonasgingivalis感染を診断および治療するための抗原複合体 |
WO2006062685A2 (en) | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
EP1828243A2 (en) | 2004-11-30 | 2007-09-05 | Gastrotech Pharma A/S | Growth hormone secretagogue receptor 1a ligands |
US20100183617A1 (en) | 2005-02-23 | 2010-07-22 | University Of Virginia Patent Foundation | Compositions and methods for regulating sas1r |
CA2549477A1 (en) | 2005-06-29 | 2006-12-29 | The Regents Of The University Of California | Competitive regulation of hepcidin mrna by soluble and cell-associated hemojuvelin |
WO2007120883A2 (en) | 2006-04-12 | 2007-10-25 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to hepcidin |
GB0610395D0 (en) | 2006-05-25 | 2006-07-05 | Ge Healthcare Ltd | Novel imaging agents |
EP2044118A2 (en) | 2006-06-13 | 2009-04-08 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
US20080019913A1 (en) | 2006-07-07 | 2008-01-24 | University Of Arizona Office Of Technology Transfer | Enkepahlin analogs with improved bioavailability |
WO2008045252A2 (en) * | 2006-10-04 | 2008-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Engineered integrin binding peptides |
US7713937B2 (en) | 2006-11-10 | 2010-05-11 | Cara Therapeutics, Inc. | Synthetic peptide amides and dimeric forms thereof |
EP2109480B1 (en) | 2006-12-07 | 2017-06-28 | The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services | Use of antagonists of the interaction between hiv gp120 and alpha4beta7 integrin |
TW201307390A (zh) | 2007-02-02 | 2013-02-16 | Amgen Inc | 海帕西啶(hepcidin)、海帕西啶拮抗劑及使用方法 |
PL2426144T3 (pl) | 2007-02-23 | 2019-05-31 | Merck Sharp & Dohme | Przeciwciała Anty-IL-23p19 wytworzone metodą inżynierii genetycznej |
US20080260820A1 (en) | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
ES2465223T3 (es) | 2007-04-27 | 2014-06-05 | Zymogenetics, Inc. | Antagonistas de IL-17A, IL-17F e IL-23P19 y procedimientos de uso |
WO2008144041A1 (en) | 2007-05-21 | 2008-11-27 | The Ohio State University Research Foundation | Hepcidins as biomarkers for impending lupus nephritis flare |
WO2009002947A2 (en) | 2007-06-22 | 2008-12-31 | Affymax, Inc. | Compounds and peptides that bind the trail receptor |
CA2692037A1 (en) | 2007-07-06 | 2009-01-15 | Valorisation Hsj, Societe En Commandite | Il-23 receptor antagonists and uses thereof |
CN101358201A (zh) | 2007-07-31 | 2009-02-04 | 钱忠明 | 重组人铁调素腺病毒、其制备方法及应用 |
CN101307085B (zh) | 2007-08-01 | 2012-06-13 | 香港理工大学深圳研究院 | 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用 |
CA2707840A1 (en) | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
GR1006896B (el) | 2007-08-24 | 2010-07-20 | Ελληνικο Ινστιτουτο Παστερ, | Μεθοδος παραγωγης μιας πεπτιδικης ορμονης |
WO2009039185A1 (en) | 2007-09-17 | 2009-03-26 | The Trustees Of Columbia University In The City Of New York | Uses of immunologically modified scaffold for tissue prevascularization and cell transplantation |
US20100280098A1 (en) | 2007-10-05 | 2010-11-04 | Juliano Rudolph L | Receptor targeted oligonucleotides |
EP2373679B1 (en) | 2008-12-05 | 2017-03-08 | The Regents of The University of California | Mini-hepcidin peptides and methods of using thereof |
DE102009007381A1 (de) | 2009-01-29 | 2010-08-05 | Amp-Therapeutics Gmbh & Co. Kg | Antibiotische Peptide |
US8999935B2 (en) | 2009-02-11 | 2015-04-07 | New York University | Treatment of osteoporosis in peri- and post-menopausal women with hepcidin |
CA2758264A1 (en) | 2009-04-08 | 2010-10-14 | Takeda Pharmaceutical Company Limited | Neuromedin u derivative |
TWI578992B (zh) | 2009-04-30 | 2017-04-21 | 諾克森製藥股份有限公司 | 與鐵調節激素(hepcidin)結合之核酸類 |
CA3008993A1 (en) | 2010-01-25 | 2011-07-28 | Cornell University | Aromatic-cationic peptides and uses of same |
US9523073B2 (en) | 2010-03-31 | 2016-12-20 | Medical Diagnostic Laboratories, Llc | Elisa for a naturally-occurring soluble truncated form of IL-23 receptor |
JP2011231085A (ja) | 2010-04-30 | 2011-11-17 | Osaka Prefecture Univ | 環状ペプチド |
US20130236977A1 (en) | 2010-05-24 | 2013-09-12 | Children's Medical Center Corporation | Compositions and methods for plasma peptide analysis |
JP5921545B2 (ja) | 2010-08-11 | 2016-05-24 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | リナクロチドの安定な製剤 |
EP2444101A1 (en) | 2010-10-21 | 2012-04-25 | Universitätsklinikum Freiburg | Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis |
WO2012101599A2 (en) | 2011-01-27 | 2012-08-02 | Ramot At Tel-Aviv University Ltd. | Glycogen synthase kinase-3 inhibitors |
US8946150B2 (en) | 2011-06-14 | 2015-02-03 | Medical Diagnostic Laboratories, LLC. | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
EP2720704A4 (en) | 2011-06-14 | 2015-06-10 | Stealth Peptides Int Inc | AROMATIC-CATIONIC PEPTIDES AND USES THEREOF |
US9605027B2 (en) | 2011-06-14 | 2017-03-28 | Medical Diagnostic Laboratories, Llc | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
US9169292B2 (en) | 2011-06-14 | 2015-10-27 | Medical Diagnostic Laboratories, Llc | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
AU2012327226C1 (en) | 2011-12-09 | 2017-03-02 | The Regents Of The University Of California | Modified mini-hepcidin peptides and methods of using thereof |
WO2013177432A1 (en) | 2012-05-23 | 2013-11-28 | The University Of Chicago | Methods of treating obesity |
US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
WO2014127316A2 (en) | 2013-02-15 | 2014-08-21 | Srx Cardio, Llc | Proprotein convertase subtilisin/kexin type 9 (pcsk9) allosteric binding ligands to mudulate serum low density lipoprotein (ldl) levels |
RS62633B1 (sr) | 2013-03-15 | 2021-12-31 | Protagonist Therapeutics Inc | Analozi hepcidina i njihove primene |
US20140294901A1 (en) | 2013-04-02 | 2014-10-02 | Protagonist Therapeutics, Inc. | Novel a4b7 peptide dimer antagonists |
US20140294902A1 (en) | 2013-04-02 | 2014-10-02 | Protagonist Therapeutics, Inc. | Novel a4b7 peptide antagonists |
LT3013351T (lt) | 2013-06-24 | 2020-01-10 | Canbas Co., Ltd. | Peptidai ir peptidomimetikai, naudojami derinyje, ir gydymo būdai, skirti vėžiu sergančių pacientų subpopuliacijoms |
WO2014210056A1 (en) | 2013-06-27 | 2014-12-31 | Stealth Peptides International, Inc. | Peptide therapeutics and methods for using same |
EP3065757A4 (en) | 2013-10-09 | 2017-08-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines |
WO2015112700A1 (en) | 2014-01-22 | 2015-07-30 | Wisconsin Alumni Research Foundation | Alpha/beta-peptide mimics of z-domain peptides |
CN106456703A (zh) | 2014-04-07 | 2017-02-22 | 摩坚瑟生物技术股份有限公司 | 铁调素模拟肽及其用途 |
JP6585162B2 (ja) | 2014-05-16 | 2019-10-02 | プロタゴニスト セラピューティクス, インコーポレイテッド | α4β7インテグリンチオエーテルペプチドアンタゴニスト |
WO2015183963A2 (en) | 2014-05-28 | 2015-12-03 | Stealth Peptides International, Inc. | Therapeutic compositions including redox-active parabenzoquinones and uses thereof |
US20170313754A1 (en) | 2014-06-27 | 2017-11-02 | Protagonist Therapeutics, Inc. | Hepcidin and mini-hepcidin analogues and uses thereof |
WO2016004093A2 (en) | 2014-07-01 | 2016-01-07 | Stealth Biotherapeutics Corp | Therapeutic compositions including galectin-3 inhibitors and uses thereof |
RU2736637C9 (ru) | 2014-07-17 | 2021-02-08 | Протагонист Терепьютикс, Инк. | Пептидные ингибиторы рецептора интерлейкина-23 для перорального приема и их применение для лечения воспалительных заболеваний кишечника |
EP3201217A4 (en) * | 2014-10-01 | 2018-07-18 | Protagonist Therapeutics Inc. | Novel cyclic monomer and dimer peptides having integrin antagonist activity |
BR112017006826A2 (pt) | 2014-10-01 | 2017-12-12 | Protagonist Therapeutics Inc | novos monômeros e dímeros peptídicos a4ss7 antagonistas |
US20170362292A1 (en) | 2014-12-29 | 2017-12-21 | The Regents Of The University Of California | S-Alkylated Hepcidin Peptides and Methods of Making and Using Thereof |
US20160199437A1 (en) | 2015-01-08 | 2016-07-14 | D. Travis Wilson | Therapeutic compositions including iron chelators and uses thereof |
WO2016115168A1 (en) | 2015-01-12 | 2016-07-21 | Synthorx, Inc. | Incorporation of unnatural nucleotides and methods thereof |
US20160228491A1 (en) | 2015-02-09 | 2016-08-11 | Stealth Biotherapeutics Corp | Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof |
WO2016195663A1 (en) | 2015-06-02 | 2016-12-08 | Stealth Peptides International, Inc. | Therapeutic compositions including bpm 31510, variants and analogues thereof, and uses thereof |
WO2016200364A1 (en) | 2015-06-08 | 2016-12-15 | Stealth Peptides International, Inc. | THERAPEUTIC COMPOSITIONS INCLUDING SkQ COMPOUNDS AND USES THEREOF |
PE20180571A1 (es) | 2015-07-15 | 2018-04-04 | Protagonist Therapeutics Inc | Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias |
US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
WO2017117411A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
US10407468B2 (en) | 2016-03-23 | 2019-09-10 | Protagonist Therapeutics, Inc. | Methods for synthesizing α4β7 peptide antagonists |
WO2018022937A1 (en) | 2016-07-27 | 2018-02-01 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases |
US20200064357A1 (en) | 2016-11-09 | 2020-02-27 | Protagonist Therapeutics, Inc. | Methods for determining and monitoring gastrointestinal inflammation |
US20200207822A1 (en) | 2017-01-18 | 2020-07-02 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
EP3681900A4 (en) | 2017-09-11 | 2021-09-08 | Protagonist Therapeutics, Inc. | OPIOID AGONIST PEPTIDES AND THEIR USES |
CA3089868A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
EP3810094A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor |
TW202019948A (zh) | 2018-07-12 | 2020-06-01 | 美商領導醫療有限公司 | 介白素-23受體之肽抑制劑及其治療發炎疾病之用途 |
TW202116793A (zh) | 2019-07-10 | 2021-05-01 | 美商領導醫療有限公司 | 介白素-23受體之肽抑制劑及其於治療發炎疾病的用途 |
-
2015
- 2015-10-01 BR BR112017006826A patent/BR112017006826A2/pt not_active Application Discontinuation
- 2015-10-01 KR KR1020177011880A patent/KR20170108936A/ko unknown
- 2015-10-01 RU RU2017114414A patent/RU2017114414A/ru not_active Application Discontinuation
- 2015-10-01 CN CN201580064273.5A patent/CN106999537B/zh active Active
- 2015-10-01 CA CA2962642A patent/CA2962642A1/en active Pending
- 2015-10-01 JP JP2017517669A patent/JP2017535527A/ja active Pending
- 2015-10-01 MX MX2017004300A patent/MX2017004300A/es unknown
- 2015-10-01 US US14/872,975 patent/US9809623B2/en active Active
- 2015-10-01 AU AU2015328002A patent/AU2015328002A1/en not_active Abandoned
- 2015-10-01 EP EP15846131.9A patent/EP3200812B8/en active Active
- 2015-10-01 SG SG11201702553RA patent/SG11201702553RA/en unknown
- 2015-10-01 WO PCT/US2015/053558 patent/WO2016054411A1/en active Application Filing
-
2016
- 2016-02-17 US US15/046,325 patent/US9518091B2/en active Active
-
2017
- 2017-03-19 IL IL251260A patent/IL251260A0/en unknown
- 2017-09-07 US US15/698,407 patent/US20180148477A1/en not_active Abandoned
-
2020
- 2020-02-04 US US16/781,516 patent/US11111272B2/en active Active
-
2021
- 2021-07-16 US US17/378,328 patent/US20220162261A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2016054411A1 (en) | 2016-04-07 |
EP3200812A1 (en) | 2017-08-09 |
US20200308229A1 (en) | 2020-10-01 |
US20220162261A1 (en) | 2022-05-26 |
SG11201702553RA (en) | 2017-04-27 |
US9809623B2 (en) | 2017-11-07 |
US20180148477A1 (en) | 2018-05-31 |
MX2017004300A (es) | 2017-12-18 |
US9518091B2 (en) | 2016-12-13 |
JP2017535527A (ja) | 2017-11-30 |
RU2017114414A3 (pt) | 2019-04-29 |
US11111272B2 (en) | 2021-09-07 |
KR20170108936A (ko) | 2017-09-27 |
RU2017114414A (ru) | 2018-11-06 |
IL251260A0 (en) | 2017-05-29 |
US20160152664A1 (en) | 2016-06-02 |
EP3200812B8 (en) | 2021-04-28 |
EP3200812B1 (en) | 2020-11-25 |
AU2015328002A1 (en) | 2017-04-27 |
CA2962642A1 (en) | 2016-04-07 |
CN106999537B (zh) | 2020-01-31 |
EP3200812A4 (en) | 2018-02-28 |
CN106999537A (zh) | 2017-08-01 |
US20160159862A1 (en) | 2016-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017006826A2 (pt) | novos monômeros e dímeros peptídicos a4ss7 antagonistas | |
CL2023000198A1 (es) | Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo | |
AU2019201173B2 (en) | Novel polypeptides | |
CY1124425T1 (el) | Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης | |
EP3960754A3 (en) | Alpha4beta7 integrin thioether peptide antagonists | |
WO2017077085A3 (en) | Immunomodulatory antibodies | |
CY1121710T1 (el) | Παρεμβασεις με βαση την αγγειοποιητινη για τη θεραπεια της εγκεφαλικης ελονοσιας | |
UA118167C2 (uk) | Пептид та його застосування | |
NZ706909A (en) | Novel α4ß7 peptide dimer antagonists | |
EA201690613A1 (ru) | Улучшенные составы на основе аденовирусов | |
NZ629394A (en) | Synthetic brassica-derived chloroplast transit peptides | |
EP3544623A4 (en) | PEPTIDIC SEQUENCES PENETRATING INTO CELLS | |
MX2017013756A (es) | Preparacion que contiene arabinoxilo-oligosacaridos. | |
EP3166959A4 (en) | Targeting peptides that bind s. mutans, constructs comprising such peptides and uses thereof | |
TR201910057T4 (tr) | Kauçuk bi̇leşi̇mleri̇ | |
TR201905787T4 (tr) | Liyofilize TAT-NR2B9C formülasyonu. | |
CY1120997T1 (el) | Πρωτεϊνες συντηξης uti | |
CY1125143T1 (el) | Νεα αλατα νιλοτινιμπης και πολυμορφα αυτων | |
CY1123754T1 (el) | Ανασυνδιασμενο mycobacterium ως ενας ανοσοθεραπευτικος παραγοντας για τη θεραπεια του καρκινου | |
WO2014041115A3 (de) | Neue, von d3 abgeleitete d-enantiomere peptide und deren verwendung | |
CY1122374T1 (el) | Βιοτινη για την θεραπευτικη αντιμετωπιση απομυελινωτικων νευροπαθειων | |
EA201692569A1 (ru) | Полимиксины с низкой степенью замещения и композиции, их содержащие | |
BR112016017644A2 (pt) | conjugados de fator vii | |
EP3416975A4 (en) | NEW ALPHA-CONOTOXIN PEPTIDES | |
SE542188C2 (en) | Supports for membrane enhanced peptide synthesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |